| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
SINGAPORE—Pfizer Asia Pacific Pte. Ltd., Glaxo WellcomeManufacturing Pte. Ltd. and Siemens Pte. Ltd. have signed on to establish a newAgency for Science, Technology and Research (A*STAR) R&D ConsortiumProgram. The consortium, Innovative Processing of Specialties andPharmaceuticals (iPSP), was launched by A*STAR's Institute of Chemical andEngineering Sciences, and will provide a platform for pharmaceutical andspecialty chemicals industry members to confront challenges such as costs,regulatory compliance and production as they seek to move drugs from trials tomarkets.
 
"ICES has built strong and deep capabilities in theunderstanding of process science and technologies, and the time is ripe forsuch depth and breadth of knowledge to be applied to the chemicals andpharmaceutical industries," Dr. Keith Carpenter, executive director of ICES,said in a press release. "By identifying common research focus, companies canmutually benefit from joint research. This will enable companies to addressindustry-wide challenges and further reinforce the competitiveness ofSingapore's chemicals industry."
 
 
The program will make use of ICES established resources,including the Kilo Scale Laboratory, a pilot-scale multipurpose continuousplant and a fully equipped development laboratory. Under the auspices of theiPSP, research will be undertaken in areas such as process analytics, qualityby design and continuous manufacturing systems. No financial details for theagreement were released.
 
 
"For Singapore manufacturing business to sustain globalcompetitiveness, employing technological advancements in the areas of energymanagement and manufacturing operations is essential. The iPSP program providesa great platform to move ideas in technology to real-world solutions," GeorgeRouthier, managing director of Pfizer Asia Pacific Pte. Ltd., said in a pressrelease.
 
The initiative also unites industry leaders in the pursuit of'next-generation manufacturing' technologies that could improve issues such ascost, quality, environmental impact and process robustness in pharmaceuticalmanufacturing processes.
 
"At a time when companies in the pharmaceutical industry arechallenged on speed in new product development, manufacturing processinnovation, consistency in product quality, regulatory conformance andenvironmental sustainability, an integrative approach to the application ofcutting-edge technologies will be crucial to future success," said Lim HockHeng, managing director of GlaxoSmithKline's Pharmaceutical Manufacturing SitesSingapore. "The launch of iPSP is very timely."
 
ICES was established in 2002 to conduct world-classscientific research, develop novel technologies and support scientists andengineers in fostering economic growth in Singapore. The organization'sresearch areas include chemistry and chemical engineering science as well as"advanced analytical characterization and measurement to develop state of theart technology for the petrochemical, general chemical, fine chemical andpharmaceutical industries."
 
 
 
 
SOURCE: ICES press release

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue